ReviewJournal of gastroenterology and hepatology2018
Terlipressin: Current and emerging indications in chronic liver disease.
Review in Journal of gastroenterology and hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07304466 (Comparison of the Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of the Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials.Medicine · 2018Pooled it
- Terlipressin Treatment for Acute Esophageal Variceal Bleeding: Bolus or Infusion?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension: a randomized, single-blind clinical trial.JHEP reports : innovation in hepatology · 2025Article
- From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.Metabolites · 2025Review
- Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.Advances in therapy · 2023Article
- Review
- Emerging Therapeutic Targets for Portal Hypertension.Current hepatology reports · 2023Review
- Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides.International journal of molecular sciences · 2022Review
- Terlipressin effect on hepatorenal syndrome: Updated meta-analysis of randomized controlled trials.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan.International journal of molecular sciences · 2021Review
- An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome.Scientific reports · 2020Article
- Effect of terlipressin on renal function in cirrhotic patients with acute upper gastrointestinal bleeding.Annals of translational medicine · 2020Article
- Long-term continuous terlipressin infusion in cirrhotic patients with hepatorenal syndrome or refractory ascites awaiting liver transplantation is associated with an increase in plasma sodium.United European gastroenterology journal · 2019Article
- Article
- Improving outcomes with pharmacotherapy to treat acute esophageal variceal bleeding.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2018Article
- Perioperative management of liver surgery-review on pathophysiology of liver disease and liver failure.European surgery : ACA : Acta chirurgica Austriaca · 2018Article
- Severe Bradycardia Associated with the Use of Terlipressin: A Case Report.Case reports in gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Terlipressin is an analogue of vasopressin that has potent vasoactive properties and has been available for use in most countries for nearly two decades. It has both established roles and emerging indications in the management of complications of decompensated chronic liver disease. We explore historic and emerging literature regarding the use of terlipressin for a range of indications including hepatorenal syndrome, portal hypertensive bleeding, and disruptions in sodium homeostasis. Novel methods of infusion-based terlipressin administration including the beneficial effect in reduction of adverse events are explored, in addition to new indications for the use of terlipressin in decompensated cirrhosis in an outpatient setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.